0
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.145.47.93. Please contact the publisher to request reinstatement.
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
RSS Email Alerts
Please Wait... Processing your request... Please Wait.

Global Health | 
M. J. Friedrich
JAMA. 2016;315(15):1554. doi:10.1001/jama.2016.3397.

JAMA Clinical Evidence Synopsis | 
Irene Tramacere, PhD; Cinzia Del Giovane, PhD; Graziella Filippini, MD
JAMA. 2016;315(4):409-410. doi:10.1001/jama.2015.18984.

Lab Reports | 
Tracy Hampton, PhD
JAMA. 2015;314(21):2226. doi:10.1001/jama.2015.16086.

News From the Food and Drug Administration | 
Rebecca Voelker, MSJ
JAMA. 2015;314(11):1108. doi:10.1001/jama.2015.11140.

Clinical Crossroads | 
Kevin P. Hill, MD, MHS
JAMA. 2015;313(24):2474-2483. doi:10.1001/jama.2015.6199.
Includes: CME, Supplemental Content

Lab Reports | 
Tracy Hampton, PhD
JAMA. 2015;313(21):2114. doi:10.1001/jama.2015.5672.

Editorial | 
Stephen L. Hauser, MD
JAMA. 2015;313(3):251-252. doi:10.1001/jama.2014.18150.

Preliminary Communication |  FREE
Richard K. Burt, MD; Roumen Balabanov, MD; Xiaoqiang Han, MD; et al.
JAMA. 2015;313(3):275-284. doi:10.1001/jama.2014.17986.
Includes: Supplemental Content

Original Investigation |  FREE
Nikolai Madrid Scheller, MB; Henrik Svanström, MSc; Björn Pasternak, MD, PhD; et al.
JAMA. 2015;313(1):54-61. doi:10.1001/jama.2014.16946.
Includes: Supplemental Content

news@JAMA | 
JAMA. 2014;311(13):1281. doi:10.1001/jama.2014.2920.

Sign in

Purchase Options

• Subscribe to the journal
• Rent this article ?

A free personal account provides

• Free current issues on The JAMA Network Reader
• Free quizzes on The JAMA Network Challenge
• Commenting and personalized alerts
From The JAMA Network
JAMA Neurology
Editorial  | 
Rebound Relapses After Ceasing Another Disease-Modifying Treatment in Patients With Multiple Sclerosis Are There Lessons to Be Learned?
Rhonda Voskuhl, MD
JAMA Neurology
Original Investigation  | 
Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment
Stacy Ellen Hatcher, BS; Emmanuelle Waubant, MD, PhD; Bardia Nourbakhsh, MD; et al.
JAMA Neurology
Editorial  | 
Alemtuzumab and Multiple Sclerosis Another Note of Caution
Reinhard Hohlfeld, MD; Tania Kümpfel, MD
JAMA Neurology
Observation  | 
Fulminant Central Nervous System Nocardiosis in a Patient Treated With Alemtuzumab For Relapsing-Remitting Multiple Sclerosis
Horst Penkert, MD; Claire Delbridge, MD; Nina Wantia, MD; et al.